2795. Cefepime Versus Meropenem for Infections Due to HECCcK-YeS-MAm Organisms with Cefepime MICs of 4-8 mCg/mL (S-DD)

BACKGROUND: Recent guidance from IDSA recommends meropenem for treatment of organisms at moderate-high risk for inducible chromosomal AmpC β-lactamase hyperproduction (AmpC organisms) with a cefepime minimum inhibitory concentration (MIC) of 4-8 mCg/mL (susceptible dose-dependent or S-DD).1 This run...

Descripción completa

Detalles Bibliográficos
Autores principales: Purdy, Andrew Scott, Howe, Zach, Desai, Armisha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677268/
http://dx.doi.org/10.1093/ofid/ofad500.2406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677268/
http://dx.doi.org/10.1093/ofid/ofad500.2406

Ejemplares similares